Xeris Biopharma Holdings, Inc. (XERS) Institutional Ownership

Ownership Summary

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) appears in 218 institutional 13F filings for the quarter ending December 2025.

• Their combined ownership stood at 55.6% of outstanding shares in December 2025, down from 56.1% in September 2025.
• Their total shares held in XERS increased 4.21% from the prior quarter, while the number of investors in Xeris Biopharma Holdings increased 36.25% year over year.
• Among the 218 funds, 111 bought more Xeris Biopharma Holdings shares, 74 sold down, and 33 held their ground.
• The aggregate institutional position in Xeris Biopharma Holdings amounted to 98.67Mn shares as of December 2025, up by 3.99Mn shares quarter on quarter, and up 26.39Mn shares year over year.
• As of December 31, 2025, the biggest holder of Xeris Biopharma Holdings is BlackRock, Inc. at 12.95Mn shares, representing 7.29% of shares outstanding.
• The most significant purchases of XERS for the quarter ending December 2025 came from ARMISTICE CAPITAL, LLC (1.91Mn), Parkman Healthcare Partners LLC (1.72Mn), MILLENNIUM MANAGEMENT LLC (1.41Mn), Rosalind Advisors, Inc. (1.12Mn), UBS Group AG (1.04Mn).
• The biggest sellers of Xeris Biopharma Holdings for the quarter ending December 2025 included DRIEHAUS CAPITAL MANAGEMENT LLC (2.08Mn), Goldman Sachs Group Inc (1.52Mn), Connor, Clark & Lunn Investment Management Ltd. (651.07K), Prudential Financial Inc (561.81K), VOLORIDGE INVESTMENT MANAGEMENT, LLC (441.01K).
• Business Quant data shows the 10 biggest positions in Xeris Biopharma Holdings as of December 2025 are held by BlackRock, Inc. (12.95Mn), D. E. Shaw & Co., Inc. (7.79Mn), State Street Corp (4.66Mn), GEODE CAPITAL MANAGEMENT, LLC (4.29Mn), Qube Research & Technologies Ltd (4.11Mn), Rosalind Advisors, Inc. (3.23Mn), Nuveen, LLC (2.92Mn), Morgan Stanley (2.57Mn), MILLENNIUM MANAGEMENT LLC (2.27Mn), WELLINGTON MANAGEMENT GROUP LLP (2.17Mn).